Latest Breaking News On - Hans schambye - Page 1 : comparemela.com

Galecto Announces First Patient Dosed In An Investigator-Initiated Phase 2 Trial Of GB1211 In Combination With Pembrolizumab

Galecto Announces First Patient Dosed In An Investigator-Initiated Phase 2 Trial Of GB1211 In Combination With Pembrolizumab
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesBrendan curtiWilliam redmondHans schambyeRobertw franzProvidence cancer instituteRobertw franz cancer centerEarlea chiles research instituteGalecto incJoseph healthMonitoring labProvidence melanoma programResearch project grantProvidence cancer institute in portlandNational institutes of healthNational cancer institute

Phase 2 Trial Shows Fibrosis Reduction in Some With Myelofibrosis

The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).

Hans schambyeClaire harrisonDifference betweenBlood cancer

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesHans schambyeAshleyr robinsonClaire harrisonJon freveExchange commissionSafety review committeeGalecto incDemonstrate reductionBone marrowTotal symptom scoreChief executive officerPrivate securities litigation reform actAnnual reportQuarterly reports

Galecto Inc (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Galecto Inc (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hans schambyeClaire harrisonGalecto incSafety review committeeTotal symptom scoreChief executive officer

Galecto Announces Plans to Explore Strategic Alternatives

BOSTON, Sept. 26, 2023 Galecto, Inc. , a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a.

United statesHans schambyeJon freveAshleyr robinsonGlobenewswire incGalecto incExchange commissionPrivate securities litigation reform actAnnual report